AssetMark’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.64K Hold
15
– – ﹤0.01% 3106
2026
Q2
$1.64K Hold
15
– – ﹤0.01% 3023
2026
Q1
$1.56K Hold
15
– – ﹤0.01% 2930
2025
Q4
$1.55K Hold
15
– – ﹤0.01% 2831
2025
Q3
$1.36K Sell
15
-1
-6% -$88 ﹤0.01% 2722
2025
Q2
$1.41K Sell
16
-51
-76% -$4.42K ﹤0.01% 2531
2025
Q1
$6.11K Sell
67
-932
-93% -$83.9K ﹤0.01% 1949
2024
Q4
$86.2K Sell
999
-5,492
-85% -$497K ﹤0.01% 1284
2024
Q3
$617K Buy
6,491
+354
+6% +$33.6K ﹤0.01% 864
2024
Q2
$561K Buy
6,137
+46
+0.8% +$4.11K ﹤0.01% 857
2024
Q1
$552K Buy
6,091
+606
+11% +$53.1K ﹤0.01% 817
2023
Q4
$446K Buy
5,485
+2,841
+107% +$223K ﹤0.01% 807
2023
Q3
$211K Buy
+2,644
New +$213K ﹤0.01% 865

Other funds holding PPH

AssetMark's PPH Position: Q3 2026 in Review

AssetMark held its VanEck Pharmaceutical ETF (PPH) position steady in Q3 2026 at 15 shares worth $1.64K. The position accounts for ﹤0.01% of the portfolio, ranked #3106.

AssetMark first reported a position in PPH in Q3 2023 and has held it in 13 quarters since. The position peaked at $617K in Q3 2024. 124 funds tracked by Wall St. Rank hold PPH as of Q3 2026.

  • AssetMark held 15 shares of VanEck Pharmaceutical ETF worth $1.64K as of Q3 2026.
  • AssetMark left its VanEck Pharmaceutical ETF share count unchanged in Q3 2026.
  • VanEck Pharmaceutical ETF made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3106 holding.
  • AssetMark first reported a position in VanEck Pharmaceutical ETF in Q3 2023 and has held it in 13 quarters since.
  • AssetMark's VanEck Pharmaceutical ETF position peaked at $617K in Q3 2024.
  • 124 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.